Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1985-3-12
|
| pubmed:abstractText |
Carbamazepine is gaining recognition as a valuable drug in the treatment of patients with bipolar disorders who fail to respond to lithium. Clinical experience in the treatment of 90 bipolar patients is described: 48% responded to lithium alone or in combination with other standard drug treatments. A subgroup of 34 lithium nonresponders were treated with carbamazepine; of these, 17 (50%) responded to carbamazepine and 5 responded to carbamazepine plus lithium, for a total response rate of 65%. Issues of side effects, blood levels, and compliance are discussed. These observations support the efficacy and safety of carbamazepine and suggest the need for well-controlled double-blind studies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0160-6689
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
58-60
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:3968046-Anemia,
pubmed-meshheading:3968046-Antidepressive Agents, Tricyclic,
pubmed-meshheading:3968046-Bipolar Disorder,
pubmed-meshheading:3968046-Carbamazepine,
pubmed-meshheading:3968046-Drug Therapy, Combination,
pubmed-meshheading:3968046-Humans,
pubmed-meshheading:3968046-Leukopenia,
pubmed-meshheading:3968046-Lithium,
pubmed-meshheading:3968046-Patient Compliance,
pubmed-meshheading:3968046-Time Factors
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants.
|
| pubmed:publicationType |
Journal Article
|